Literature DB >> 1404646

Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.

N J Vogelzang1, E R Priest, L Borden.   

Abstract

Spontaneous regression of biopsy proved metastatic renal cell carcinoma is rare. We describe a 39-year-old man who had histologically proved metastatic disease to the lungs after nephrectomy. The lesions had spontaneously regressed 3 months later. The patient remained without evidence of recurrence 5 years after diagnosis.

Entities:  

Mesh:

Year:  1992        PMID: 1404646     DOI: 10.1016/s0022-5347(17)36874-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.

Authors:  Mamta Parikh; Poornima Bajwa
Journal:  Semin Nephrol       Date:  2020-01       Impact factor: 5.299

2.  Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts.

Authors:  Paul G Werthmann; Lothar Kindermann; Gunver S Kienle
Journal:  Complement Med Res       Date:  2019-03-20       Impact factor: 1.211

Review 3.  Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.

Authors:  Bryden Considine; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2019-03-08       Impact factor: 5.075

4.  Role of immunotherapy in metastatic renal cell cancer: past, present and future.

Authors:  Amos Lal; Kamal Kant Sahu; Vishal Jindal; Ajay Kumar Mishra; Ahmad Daniyal Siddiqui
Journal:  Ann Transl Med       Date:  2019-12

Review 5.  Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.

Authors:  Matthew Weinstock; David McDermott
Journal:  Ther Adv Urol       Date:  2015-12

Review 6.  Allogeneic stem-cell transplantation in renal-cell carcinoma.

Authors:  B M Hayes-Lattin; R T Maziarz; T M Beer
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 7.  Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.

Authors:  Xin Gao; David F McDermott
Journal:  Expert Opin Biol Ther       Date:  2018-08-30       Impact factor: 4.388

8.  Can the clinical course of cancer be influenced by non-antineoplastic drugs?

Authors:  L J Brandes; L A Friesen
Journal:  CMAJ       Date:  1995-09-01       Impact factor: 8.262

Review 9.  The application of high-dose interleukin-2 for metastatic renal cell carcinoma.

Authors:  David F McDermott
Journal:  Med Oncol       Date:  2009-01-16       Impact factor: 3.064

10.  Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.

Authors:  J Carlos Arroyo; Fernando Gabilondo; Luis Llorente; Marco A Meraz-Ríos; Carmen Sánchez-Torres
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.